Thousands of men with advanced prostate cancer will be denied a life-extending drug after officials deemed it was not cost-effective. The drug abiraterone cuts the risk of men dying within three years by a third. The drug, developed by the Institute of Cancer Research in London, works by blocking the production of testosterone, slowing down cancer growth and spread. Prostate cancer affects about 50,000 men a year in the UK and kills 12,000. The drug, developed by the Institute of Cancer Research in London, works by blocking the production of testosterone, slowing down cancer growth and spread.

Source: Daily Mail June 26, 2020 21:02 UTC